Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: A Cornerstone in Precision Oncology

Scientists summarize the key poly-(ADP-ribose) polymerase inhibitors, which act in cells with defects in homologous recombination DNA repair caused by genomic aberrations such as BRCA mutations, that are published and ongoing trials in prostate cancer.